Kwality Pharmaceuticals Reports 32% YoY Revenue Growth in H1 FY26, Expects Continued Momentum in Q3

Kwality Pharmaceuticals Ltd (KPL) reported a 32% year-on-year increase in consolidated revenue for the first half of FY26, reaching 224 crore from 170 crore in H1 FY25. The growth was driven by strong sales of registered products across key international markets, supported by an expanding product portfolio and enhanced geographic reach. EBITDA increased by 35% year-on-year, from 237 crore in H1 FY25 to 250 crore in H1 FY26, reflecting improved scale and mix optimization. EBITDA margins improved to 22.5% from 22.0% last quarter, and net profit rose from 17 crore in H1FY25 to 26 crore in H1FY26. The company accelerated its R&D and clinical initiatives, initiated multiple Bioequivalence (BE), Pharmacoequivalence (PE), and clinical trial programs across both injectables and oral solid dosage (OSD) segments, and advanced its strategic capex program. KPL generated a cash surplus of approximately 230 crore during the quarter. The company expects continued growth momentum in Q3 FY26, driven by higher order inflows, new product launches, and scale-up across international markets, with revenue projected to be around 140 crore. Management remains confident of sustaining its growth trajectory and exceeding the 2500 crore revenue target for the full year, while maintaining double-digit profitability and robust cash generation to fund ongoing expansion.